George Church (Mary Altaffer/AP Images)

Bay­er backs a George Church spin­out try­ing to turn lab-in­vent­ed amino acids in­to a new class of pro­tein ther­a­pies

Six years ago, Daniel Man­dell ap­peared on NPR to talk about an in­ven­tion out of Juras­sic Park.

As Crich­ton and Gold­blum fans re­call, In­ter­na­tion­al Ge­net­ic Tech­nolo­gies, Inc.’s con­tin­gency plan to make sure di­nosaurs didn’t es­cape was to take away their abil­i­ty to make the amino acid ly­sine, forc­ing them to re­ly on ly­sine sup­ple­ments from the park staff for sur­vival.

Man­dell, a fel­low at George Church’s Har­vard lab, took the idea a step fur­ther. He, Church and a team of sci­en­tists en­gi­neered a bac­te­ria de­pen­dent on an ar­ti­fi­cial amino acid that didn’t ex­ist any­where; sci­en­tists had in­vent­ed it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.